Reading Time: 2 minutes

The new HIV injection was for the first time on 31st March 2022, tested on a Kenyan patient three months after it was approved by the UK and the US.

The Injectable HIV Treatment   is undergoing trials in three countries in Africa; Kenya, Uganda and South Africa. This treatment has been described as  a huge milestone and the management of the disease has become more promising.

The injection was approved by U.S FDA and according to Prof. Linda Gail-Bekker is thought to be 89% more effective and is a rather more advantageous option for people who struggle with adherence to daily pills.

New HIV Injection Tested On Kenyan Patient

 The treatment is a combination of two medications; Cabotegravir and rilpivirine the Injectable HIV Treatment was developed in America. Currently; Europe, Canada and the USA are already administering it as a prescription after successful trials were conducted. 

The Injectable HIV Treatment is administered through two shots in a month and already 16 countries have undergone clinical trials. The Treatment is not a replacement for ARVs but a more effective way of treating the disease. The injectable treatment is estimated to cost around 22,000$ in a year and patients are calling on the government to help cover for most of the cost. 

In Kenya, the treatment option is being carried out in three centres and Agha Khan Hospital has  about 40 people undergoing trials. Other centres in the country include; Kenyatta Hospital in Nairobi  and Empath Hospital in Eldoret. On March 31 2022, first Kenyan patient underwent the clinical trial successfully at Agha Khan Hospital. 

” This is groundbreaking, game changing and revolutionary”, Dr. David Rosenthal described the treatment.  

New HIV Injection Tested On Kenyan Patient

Prof. Cholesterol Orkin  a clinical professor in HIV at Queen Mary University of London explains 

that the treatment will help destigmatize the disease and patients will become more relieved of the burden of taking daily tablets, “they will be taking medication twelve times instead of 365 times”. She explained.

Cabotegravir and rilpivirine side effects as reported by patients are headache, raised temperature, feeling hot,  pain, bumps and swelling.

When taking standard HIV treatment, the patient needs to take tablets every 24 hours to have enough levels of the medications in the blood. Injectable Cabotegravir and rilpivirine  have long half-lives; they can stay in the body for much longer than the tablets. These  injections every one or two months are enough to maintain high enough blood levels of the medication to suppress HIV.

Leave a Reply

Your email address will not be published.

Social media & sharing icons powered by UltimatelySocial